News Image

What's going on in today's pre-market session

By Mill Chart

Last update: May 22, 2023

The US market session of Monday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.

Today's pre-market gainers

TickerChangeComment
BHG7.0K%BRIGHT HEALTH GROUP INC's (NYSE:BHG) shares rose 7.0K% to $14.0 during Monday's pre-market session. Also in the previous session NYSE:BHG had a very good day: shares closed with a 15.26% gain.
ADMP6.0K%ADAMIS PHARMACEUTICALS CORP's (NASDAQ:ADMP) shares rose 6.0K% to $3.24 during Monday's pre-market session. After yesterday's drop of -26.47%, it looks like it is bouncing back in today's pre-market session.
HEPA71.29%HEPION PHARMACEUTICALS INC's (NASDAQ:HEPA) shares rose 71.29% to $15.2 during Monday's pre-market session. The stock is trading 38.35% lower than a month ago.
AVRO69.01%AVROBIO INC's (NASDAQ:AVRO) stock price is advancing with 69.01% to a price of $1.31. Earlier today the company had a press release: AVROBIO Announces Agreement to Sell Cystinosis Gene Therapy Program for $87.5 Million.
SQL40.77%SEQLL INC's (NASDAQ:SQL) stock price increased by 40.77% to $0.47. After yesterday's drop of -13.29%, it looks like it is bouncing back in today's pre-market session.
CNSP28.3%CNS PHARMACEUTICALS INC (NASDAQ:CNSP) rose 28.3% to $2.04 during Monday's pre-market session. This is a continuation of yesterday's gain of 17.78%.
NCPL26.02%NETCAPITAL INC's (NASDAQ:NCPL) stock price is advancing with 26.02% to a price of $2.47. In the last month the share price increased with 122.0%.
IMMX23.17%IMMIX BIOPHARMA INC's (NASDAQ:IMMX) stock price is advancing with 23.17% to a price of $2.02. Only yesterday these shares were declining by -14.14%, so we see a bit of recovery today.
NBSE21.69%NEUBASE THERAPEUTICS INC (NASDAQ:NBSE) rose 21.69% to $0.23 during Monday's pre-market session. In the last month the share price increased with 23.77%.
ZVSA18.38%ZYVERSA THERAPEUTICS INC's (NASDAQ:ZVSA) shares rose 18.38% to $0.5. Yesterday's gain of 14.23% continues in today's pre-market with 18.38%.

To see the full list of premarket gainers you can use our premarket gainers screener.

Today's pre-market losers

TickerChangeComment
MNK-22.38%MALLINCKRODT PLC's (NYSEARCA:MNK) stock price is declining with 22.38% to a price of $4.89. Prices are quite volatile now: this is a reversal from yesterday's 458.0% gain.
SGTX-18.32%SIGILON THERAPEUTICS INC's (NASDAQ:SGTX) stock price is declining with 18.32% to a price of $0.52. After yesterdays gain of 10.71%, it goes down with 18.32% in today's pre-market session.
NTB-16.83%BANK OF N.T. BUTTERFIELD&SON's (NYSE:NTB) stock price decreased by 16.83% to $20.91. Shareholders saw the stock price going 32.05% lower in the past 3 months.
RNAZ-16.03%TRANSCODE THERAPEUTICS INC's (NASDAQ:RNAZ) shares fell 16.03% to $0.24. A press release (TransCode Therapeutics Announces 1-for-20 Reverse Stock Split) was released earlier today.
BIOC-14.74%BIOCEPT INC's (NASDAQ:BIOC) shares fell 14.74% to $5.67 during Monday's pre-market session. After running up 21.24% in yesterday's session, NASDAQ:BIOC is pulling back pre-market.
ICPT-12.61%INTERCEPT PHARMACEUTICALS IN's (NASDAQ:ICPT) shares fell 12.61% to $11.85. In the last month the share price dropped with 27.02%.
BXRX-12.16%BAUDAX BIO INC's (NASDAQ:BXRX) shares fell 12.16% to $0.56. In the last month the share price dropped with 73.98%.
BJDX-12.13%BLUEJAY DIAGNOSTICS INC's (NASDAQ:BJDX) shares fell 12.13% to $0.24 during Monday's pre-market session. Shareholders saw the stock price going 66.22% lower in the past 3 months.
FLGC-10.19%FLORA GROWTH CORP's (NASDAQ:FLGC) shares fell 10.19% to $0.23. In the last 3 months the stock lost 39.53%.
JCSE-10.0%JE CLEANTECH HOLDINGS LTD's (NASDAQ:JCSE) stock price decreased by 10.0% to $0.72. After running up 25.96% in yesterday's session, NASDAQ:JCSE is pulling back pre-market.

For the full premarket loser list go to our premarket losers screener.

Back

IMMIX BIOPHARMA INC

NASDAQ:IMMX (4/24/2024, 7:09:36 PM)

2.13

-0.17 (-7.39%)

IMMX News

News Image6 days ago - Immix Biopharma, Inc.Immix Biopharma on Track to Dose NXC-201 Patients in United States
News Image6 days ago - Immix Biopharma, Inc.Immix Biopharma on Track to Dose NXC-201 Patients in United States

Scheduling U.S. site initiation visits April and May 2024On track to dose relapsed/refractory AL Amyloidosis patients with CAR-T NXC-201 at New...

News Image9 days ago - Immix Biopharma, Inc.Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)

Updated clinical data for next-generation CAR-T NXC-201 in relapsed/refractory AL amyloidosis will be presented in Baltimore May 7-11, 2024 LOS ANGELES,...

News Image23 days ago - InvestorPlaceIMMX Stock Earnings: Immix Biopharma Misses EPS for Q4 2023

IMMX stock results show that Immix Biopharma missed analyst estimates for earnings per share the fourth quarter of 2023.

News Image23 days ago - BusinessInsiderIMMX Stock Earnings: Immix Biopharma Misses EPS for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Immix Biopharma (NASDAQ:IMMX) just reported results for the fourth quarter of 2...

News Imagea month ago - Immix Biopharma, Inc.Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial
News Imagea month ago - Immix Biopharma, Inc.Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial

LOS ANGELES, CA, March 20, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a...

News Image2 months ago - Immix Biopharma, Inc.Immix Biopharma Announces “Be Proactive in AL” AL Amyloidosis Awareness Initiative

Hear from the ~30,000 relapsed or refractory AL Amyloidosis patients in the United States today in their own words

News Image2 months ago - Immix Biopharma, Inc.Immix Biopharma Announces “Be Proactive in AL” AL Amyloidosis Awareness Initiative

Hear from the ~30,000 relapsed or refractory AL Amyloidosis patients in the United States today in their own words...

News Image2 months ago - Immix Biopharma, Inc.Immix Biopharma 12 Month Review Progress Update

LOS ANGELES, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX), a clinical-stage biopharmaceutical company trailblazing cell...

News Image3 months ago - Immix Biopharma, Inc.Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock
News Image3 months ago - Immix Biopharma, Inc.Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock

LOS ANGELES, CA, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage...

IMMX Links
Follow us for more